This study is about a new medicine called **pelacarsen** (TQJ230) to help people with **high Lp(a) levels**. Lp(a) stands for **Lipoprotein(a)**, a type of fat in your blood that can increase heart problems. The study is for Black/African American and Hispanic people who already have heart or blood vessel diseases. These diseases are known as **ASCVD** (Atherosclerotic Cardiovascular Disease). The study will compare pelacarsen to a placebo (a harmless pill) to see if it can lower Lp(a) levels.

Participants will first go through a **30-day screening** period to ensure they meet the health requirements. After that, there might be another **30-day period** to check if their other heart treatments are stable. The main part of the study lasts **12 months,** where participants will receive either pelacarsen or a placebo. After treatment, there is a **16-week follow-up** period.

• Participants must be 18-80 years old and have high Lp(a) levels.
• They should already be receiving care for other heart risk factors.
• Participants with serious health issues like uncontrolled blood pressure or severe liver or kidney disease cannot join.